UCFA
GYRE icon

United Capital Financial Advisors’s Gyre Therapeutics GYRE Stock Holding History

United Capital Financial Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,333
Closed -$18K – 1108
2022
Q2 		$18K Buy
+1,333
New +$8.86K ﹤0.01% 1108

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

United Capital Financial Advisors's GYRE Position: Q3 2022 in Review

United Capital Financial Advisors sold out of Gyre Therapeutics (GYRE) in Q3 2022, closing a stake of 1,333 shares — an estimated $18K sold.

United Capital Financial Advisors first reported a position in GYRE in Q2 2022 and held it in 1 quarter. The position peaked at $18K in Q2 2022. 35 funds tracked by Wall St. Rank hold GYRE as of Q3 2022.

  • United Capital Financial Advisors reported no remaining Gyre Therapeutics position as of Q3 2022 after selling out during the quarter.
  • United Capital Financial Advisors sold 1,333 Gyre Therapeutics shares in Q3 2022, an estimated $18K.
  • United Capital Financial Advisors first reported a position in Gyre Therapeutics in Q2 2022 and held it in 1 quarter.
  • United Capital Financial Advisors's Gyre Therapeutics position peaked at $18K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2022.

Based on United Capital Financial Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.